XC268BG Uses, Dosage, Side Effects and more
XC268BG, also known as bisamide derivative of dicarboxylic acid (BDDA), is a complexing agent that has been found to chelate metal ions, including calcium, copper, iron, magnesium, and zinc. This drug has shown regenerative properties and restoration of the function of various tissues and organs. It is has been investigated in the clinical trials of NCT04428593 (Study to Assess Safety, Tolerability and Pharmacokinetics of XC268BG in Healthy Volunteers) and NCT04527354 (Pilot Study to Assess Efficacy and Safety of XC268BG in the Rehabilitation of Patients After COVID-19 Pneumonia) by PHARMENTERPRISES.
| Trade Name | XC268BG |
| Generic | Treamid |
| Treamid Other Names | BDDA, Bisamide derivative of dicarboxylic acid, XC268BG |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
How XC268BG works
In animal studies, treamid displays a positive effect on the capillaries of lungs, exhibits anti-fibrotic activity, and increases the number of endothelial progenitor cells in the lungs of animals with pulmonary fibrosis. Currently, the drug is being investigated against COVID-19.
